ECSP21093541A - Compuestos para el tratamiento de enfermedades y trastornos asociados con braf - Google Patents

Compuestos para el tratamiento de enfermedades y trastornos asociados con braf

Info

Publication number
ECSP21093541A
ECSP21093541A ECSENADI202193541A ECDI202193541A ECSP21093541A EC SP21093541 A ECSP21093541 A EC SP21093541A EC SENADI202193541 A ECSENADI202193541 A EC SENADI202193541A EC DI202193541 A ECDI202193541 A EC DI202193541A EC SP21093541 A ECSP21093541 A EC SP21093541A
Authority
EC
Ecuador
Prior art keywords
braf
disorders
compounds
treatment
associated diseases
Prior art date
Application number
ECSENADI202193541A
Other languages
English (en)
Inventor
Andrew T Metcalf
Adam W Cook
David A Moreno
Brett Joseph Prigaro
Ellen Laird
Patrick Barbour
Spencer Phillip Pajk
Bradley Jon Newhouse
Katie Keaton Brown
Erik James Hicken
Eugene Tarlton
Li Ren
Dean Russell Kahn
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of ECSP21093541A publication Critical patent/ECSP21093541A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Se adjunta resumen de la invención
ECSENADI202193541A 2019-06-28 2021-12-28 Compuestos para el tratamiento de enfermedades y trastornos asociados con braf ECSP21093541A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962868581P 2019-06-28 2019-06-28
US202063021410P 2020-05-07 2020-05-07

Publications (1)

Publication Number Publication Date
ECSP21093541A true ECSP21093541A (es) 2022-01-31

Family

ID=71465389

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202193541A ECSP21093541A (es) 2019-06-28 2021-12-28 Compuestos para el tratamiento de enfermedades y trastornos asociados con braf

Country Status (20)

Country Link
US (2) US11414404B2 (es)
EP (1) EP3990437A1 (es)
JP (1) JP7169469B2 (es)
KR (1) KR20220011712A (es)
CN (1) CN114026073A (es)
AU (1) AU2020302352B2 (es)
BR (1) BR112021025102A2 (es)
CA (1) CA3144859C (es)
CO (1) CO2021017438A2 (es)
CR (1) CR20210626A (es)
CU (1) CU20210098A7 (es)
EC (1) ECSP21093541A (es)
IL (1) IL288214A (es)
MA (1) MA56387A (es)
MX (1) MX2021015903A (es)
PE (1) PE20220341A1 (es)
TW (1) TWI817018B (es)
UY (1) UY38767A (es)
WO (1) WO2020261156A1 (es)
ZA (1) ZA202201329B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI817018B (zh) * 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
BR112022011123A2 (pt) * 2019-12-10 2022-08-23 Hoffmann La Roche Composto, processo para a preparação de um composto, usos de um composto, métodos para o tratamento de câncer e invenção
CR20220252A (es) * 2019-12-10 2022-07-11 Hoffmann La Roche Nuevos inhibidores de braf como rompedores de la paradoja
MX2022015703A (es) 2020-06-09 2023-01-24 Array Biopharma Inc Compuestos para el tratamiento de enfermedades y trastornos asociados a braf.
TWI825637B (zh) 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶－１，６（２ｈ，７ｈ）－二酮
KR20240005899A (ko) * 2021-06-09 2024-01-12 에프. 호프만-라 로슈 아게 암 치료를 위한 병용요법
WO2023078881A1 (en) * 2021-11-04 2023-05-11 F. Hoffmann-La Roche Ag Novel use of quinazolinone compound for the treatment of cancer
WO2023105371A1 (en) * 2021-12-08 2023-06-15 Array Biopharma Inc. Crystalline form of n-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
WO2024054591A1 (en) * 2022-09-07 2024-03-14 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI350285B (en) 2002-03-13 2011-10-11 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
PL1689387T3 (pl) 2003-11-19 2012-02-29 Array Biopharma Inc Bicykliczne inhibitory MEK i sposoby ich otrzymywania
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
CN101048388A (zh) 2004-08-31 2007-10-03 阿斯利康(瑞典)有限公司 喹唑啉酮衍生物及其作为B－Raf抑制剂的用途
EP2361905B1 (en) 2005-05-18 2013-03-06 Array Biopharma Inc. Heterocyclic Inhibitors of MEK and methods of use thereof
EP2007736A1 (en) 2006-04-05 2008-12-31 AstraZeneca AB Substituted quinazolines with anti-cancer activity
EP2007737A2 (en) 2006-04-05 2008-12-31 AstraZeneca AB Chemical compounds
WO2007119055A1 (en) 2006-04-18 2007-10-25 Astrazeneca Ab Quinazolin-4-one derivatives, process for their preparation and pharmaceutical compositions containing them
US20100190777A1 (en) 2007-07-17 2010-07-29 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2012118492A1 (en) * 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
EP2776037B1 (en) 2011-11-11 2019-01-09 Novartis AG Method of treating a proliferative disease
ES2699351T3 (es) 2014-01-17 2019-02-08 Novartis Ag Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2
CN105899493B (zh) 2014-01-17 2019-03-29 诺华股份有限公司 用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
WO2017117680A1 (en) 2016-01-06 2017-07-13 Trillium Therapeutics Inc. Novel fluorinated quinazoline derivatives as egfr inhibitors
JP7219218B2 (ja) 2016-12-22 2023-02-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規のベンジルアミノ置換キナゾリンおよびｓｏｓ１阻害剤としての誘導体
JP7394768B2 (ja) * 2017-09-20 2023-12-08 エイビーエム セラピューティックス コーポレイション キナーゼ阻害剤としての環状イミノピリミジン誘導体
JP2020536881A (ja) 2017-10-12 2020-12-17 レヴォリューション・メディスンズ，インコーポレイテッド アロステリックｓｈｐ２阻害剤としてのピリジン、ピラジンおよびトリアジン化合物
WO2019071351A1 (en) 2017-10-12 2019-04-18 Trillium Therapeutics Inc. NOVEL 4-ARYLOXYQUINAZOLINE FLUORIN DERIVATIVES AS EGFR INHIBITORS USEFUL FOR THE TREATMENT OF CANCERS
UY38349A (es) 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
US11385181B2 (en) 2018-09-14 2022-07-12 Conopco, Inc. Evaluating the efficacy of leave-on cosmetic compositions to protect skin from pollutants
TWI817018B (zh) * 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物

Also Published As

Publication number Publication date
AU2020302352B2 (en) 2023-03-23
US20220289721A1 (en) 2022-09-15
CN114026073A (zh) 2022-02-08
WO2020261156A1 (en) 2020-12-30
MA56387A (fr) 2022-05-04
PE20220341A1 (es) 2022-03-14
ZA202201329B (en) 2023-09-27
CR20210626A (es) 2022-02-08
US20200407344A1 (en) 2020-12-31
BR112021025102A2 (pt) 2022-01-25
JP2022539056A (ja) 2022-09-07
TW202114996A (zh) 2021-04-16
TWI817018B (zh) 2023-10-01
JP7169469B2 (ja) 2022-11-10
CO2021017438A2 (es) 2022-01-17
US11634409B2 (en) 2023-04-25
KR20220011712A (ko) 2022-01-28
CA3144859A1 (en) 2020-12-30
UY38767A (es) 2021-01-29
CU20210098A7 (es) 2022-06-06
IL288214A (en) 2022-01-01
EP3990437A1 (en) 2022-05-04
US11414404B2 (en) 2022-08-16
AU2020302352A1 (en) 2022-01-20
MX2021015903A (es) 2022-02-03
CA3144859C (en) 2023-09-12

Similar Documents

Publication Publication Date Title
ECSP21093541A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados con braf
CL2021000343A1 (es) Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128)
MA49682A (fr) Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp
EA201790992A1 (ru) Иммунорегуляторные агенты
MD3209309T2 (ro) Compoziții care conțin tulpini bacteriene
EA201892740A2 (ru) Полифторзамещенное соединение в качестве ингибитора тирозинкиназы брутона (btk)
EA201692436A1 (ru) Медицинское применение
MA54229A (fr) Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp
MA52219A (fr) Traitement de l'hidradénite suppurée à l'aide d'inhibiteurs de jak
IL276383B1 (en) Treatment of ophthalmological diseases
EA201792604A1 (ru) Ингибиторы аутотаксина и их применения
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
MA55143A (fr) Composés aryl-aniline et hétéroaryl-aniline pour le traitement de cancers de la peau
CL2022000967A1 (es) Composiciones y métodos para el tratamiento de enfermedades hepáticas
DOP2016000120A (es) Nuevos inhibidores de dgat2
CL2021001198A1 (es) Compuestos heteroaromáticos como inhibidores de vanina
IL279397A (en) New compounds and their pharmaceutical preparations for the treatment of diseases
EA201792610A1 (ru) Способ лечения неврологического заболевания
CL2023000892A1 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b (divisional).
EA202190576A1 (ru) Полиморфные соединения и их применение
ECSP19066721A (es) Inhibidores duales de magl y faah
MA54741A (fr) Composés thiényl-aniline destinés au traitement d'affections de la peau
MX2021003643A (es) Derivados de terpenoides y usos de los mismos.
MA50495A (fr) Composés bicycliques à fusion 5,6 et compositions pour le traitement de maladies parasitaires
EA202090266A1 (ru) Ингибиторы mpo для применения в медицине